- Home
- NCL vs ALBT Comparison
NCL vs ALBT Comparison
Compare NCL & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCL | ALBT |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.3M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NCL | ALBT |
|---|---|---|
| Price | $0.15 | $0.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 173.7K | ★ 8.2M |
| Earning Date | 11-14-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,349,854.00 | $1,333,403.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.86 | 6.19 |
| 52 Week Low | $0.10 | $0.42 |
| 52 Week High | $1.47 | $5.35 |
Technical Indicators
Market Signals| Indicator | NCL | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 41.33 |
| Support Level | $0.14 | $0.48 |
| Resistance Level | $0.17 | $0.93 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 64.71 | 16.57 |
Price Performance
Historical ComparisonAbout NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.